Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer

Siqi Chen, Ping Xie, Matthew Cowan, Hao Huang, Horacio Cárdenas, Russell Keathley, Edward J. Tanner, Gini F. Fleming, John W. Moroney, Alok Pant, Azza M. Akasha, Ramana V. Davuluri, Masha Kocherginsky, Bin Zhang, Daniela MateiJournal of Clinical Investigation 2022 · DOI

TL;DR

This study investigated a novel combination therapy for platinum-resistant ovarian cancer (OC), pairing a hypomethylating agent (guadecitabine) with an immune checkpoint inhibitor (pembrolizumab). The approach showed feasibility and induced a clinical benefit in a subset of patients, suggesting that epigenetic priming can enhance anti-tumor immunity by modulating the tumor microenvironment and immune cell populations.

What Problem Does This Paper Address?

Ovarian cancer (OC) has been notoriously resistant to immunotherapy, particularly immune checkpoint inhibitors (ICIs) like pembrolizumab. This lack of response is thought to be due to a highly immunosuppressive tumor microenvironment (TME) that effectively "hides" cancer cells from the immune system. The challenge is to find ways to "awaken" the immune system and make these "cold" tumors more susceptible to ICI therapy. This paper addresses this by exploring whether targeting epigenetic modifications, specifically DNA methylation, can prime the tumor microenvironment to be more receptive to ICI treatment.

Methods

The study employed a Phase II clinical trial design, administering guadecitabine (a hypomethylating agent) followed by pembrolizumab to patients with platinum-resistant OC. Key techniques included:

  • Clinical Trial Design: A non-randomized, open-label, 2-stage Phase II trial to assess the safety and efficacy of the combination therapy.
  • Genomic and Transcriptomic Analysis:
    • Pyrosequencing: Used to measure LINE-1 methylation in peripheral blood mononuclear cells (PBMCs) to assess global DNA hypomethylation.
  • Infinium Human MethylationEPIC Beadchip array: Employed for genome-wide methylation profiling of tumor biopsies before and after treatment.
  • RNA-Seq: Performed on paired tumor biopsies to analyze differential gene expression and identify activated pathways.
  • High-Dimensional Immune Profiling:
    • Mass Cytometry (CyTOF) and Spectral Cytometry (CyTEK): Used to perform detailed analysis of immune cell subsets in PBMCs and tumor tissues, characterizing their phenotypes and frequencies.
  • FlowSOM, SPADE, and CITRUS algorithms: Advanced computational tools for unsupervised clustering and analysis of complex cytometry data, identifying distinct immune cell populations and their functional states.
  • Multiplex Immunohistochemistry (mIHC): Utilized to visualize and quantify the spatial distribution and co-localization of various immune cells and tumor markers within tumor tissue sections.

Datasets

  • Patient Cohort: 45 patients with recurrent, platinum-resistant ovarian cancer were enrolled. Translational analyses were performed on samples from a subset of these patients (e.g., 35 evaluable for clinical benefit, 11 for paired tumor methylation, 9 for paired tumor transcriptomics, 10 for PBMC CyTOF, 15 for extended PBMC spectral cytometry, and 5 for mIHC).
  • Publicly Available Data: Not explicitly mentioned as training datasets, but the study references existing literature and databases for pathway enrichment analysis (e.g., WikiPathways).

Key Insights and Ideas

  • Epigenetic Priming as a Strategy: The core idea is that hypomethylating agents can "reawaken" silenced genes, including those involved in immune recognition and response, making tumors more visible to ICIs.
  • Shifting the Tumor Microenvironment: The combination therapy appears to shift the TME from an immunosuppressive state to one that is more conducive to anti-tumor immunity.
  • Predictive Immune Signatures: The study identified potential baseline immune cell signatures (e.g., specific CD4+ T cell subsets, classical monocytes) that may predict a patient's likelihood of benefiting from this therapy.
  • Role of B Cells and Tertiary Lymphoid Structures (TLSs): The presence of CD20+ B cells and TLSs in tumors was strongly associated with a durable clinical benefit, suggesting a crucial, and perhaps underappreciated, role for B cells in ICI response.
  • Complex Immune Interactions: The findings highlight intricate interactions between tumor cells and various immune cell populations, influenced by epigenetic modifications and ICI treatment.

Key Results

  • Clinical Benefit: A clinical benefit rate (CBR) of 31.4% was observed in 35 evaluable patients, with 8.6% achieving partial responses and 22.9% stable disease. The median duration of clinical benefit was 6.8 months.
  • Biomarker Evidence of Immune Activation:
    • Hypomethylation: Guadecitabine successfully induced hypomethylation of LINE-1 elements in PBMCs and global hypomethylation in tumor tissues.
  • Transcriptomic Changes: RNA-Seq revealed upregulation of genes associated with anti-tumor immunity, including cytokines like IFNG and CXCL9, and immune cell markers.
  • Immune Cell Profiling: Patients with a durable CBR showed a higher frequency of naive and central memory CD4+ T cells and classical monocytes at baseline.
  • Tumor Microenvironment Features: A higher baseline density of CD8+ T cells and CD20+ B cells, and the presence of tertiary lymphoid structures (TLSs) in tumors, were associated with a durable CBR.
  • PD-L1 and A2AR Modulation: Increased PD-L1 expression was observed in post-treatment tumors from responders, and A2AR expression was reduced on CD8+ T cells, suggesting modulation of key immune checkpoints.

Limitations and Future Work

  • Limited Sample Size: The Phase II study had a relatively small number of patients, particularly for detailed translational analyses, which limits the statistical power for definitive conclusions.
  • Feasibility vs. Efficacy: While feasible and showing some clinical benefit, the regimen did not demonstrate sufficient activity for immediate advancement to larger trials, suggesting the need for further optimization.
  • Unanswered Questions: The precise functional status of B cells and TLSs, and the mechanisms by which HMAs might upregulate immunosuppressive transcripts like LAG3 and IDO1, require further investigation.
  • Future Directions:
    • Combination Therapies: The authors suggest exploring 3-drug combinations that might include additional blocking strategies for LAG3, IDO1, or A2AR to overcome potential compensatory immunosuppression.
  • Patient Selection: Further validation of baseline immune cell signatures (CD4+ T cells, monocytes) and tumor features (B cells, TLSs) for patient selection is warranted.
  • Mechanism of Action: Deeper investigation into the interplay between epigenetic modifications, immune cell function, and the tumor microenvironment is needed.
  • A2AR Inhibition: The potential of A2AR inhibitors in combination with ICIs for refractory OC warrants further study.

Summary updated

Abstract

BackgroundImmune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC). To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study.MethodsEligible patients had platinum-resistant OC, normal organ function, measurable disease, and received up to 5 prior regimens. The treatment included guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200 mg i.v.) on day 5, every 21 days. The primary endpoint was the response rate. Tumor biopsies, plasma, and PBMCs were obtained at baseline and after treatment.ResultsAmong 35 evaluable patients, 3 patients had partial responses (8.6%), and 8 (22.9%) patients had stable disease, resulting in a clinical benefit rate of 31.4% (95% CI: 16.9%-49.3%). The median duration of clinical benefit was 6.8 months. Long-interspersed element 1 (LINE1) was hypomethylated in post-treatment PBMCs, and methylomic and transcriptomic analyses showed activation of antitumor immunity in post-treatment biopsies. High-dimensional immune profiling of PBMCs showed a higher frequency of naive and/or central memory CD4+ T cells and of classical monocytes in patients with a durable clinical benefit or response (CBR). A higher baseline density of CD8+ T cells and CD20+ B cells and the presence of tertiary lymphoid structures in tumors were associated with a durable CBR.ConclusionEpigenetic priming using a hypomethylating agent with an ICI was feasible and resulted in a durable clinical benefit associated with immune responses in selected patients with recurrent OC.Trial registrationClinicalTrials.gov NCT02901899.FundingUS Army Medical Research and Material Command/Congressionally Directed Medical Research Programs (USAMRMC/CDMRP) grant W81XWH-17-0141; the Diana Princess of Wales Endowed Professorship and LCCTRAC funds from the Robert H. Lurie Comprehensive Cancer Center; Walter S. and Lucienne Driskill Immunotherapy Research funds; Astex Pharmaceuticals; Merck & Co.; National Cancer Institute (NCI), NIH grants CCSG P30 CA060553, CCSG P30 CA060553, and CA060553.
BibTeX
@article{chen2022epigenetic,
  author = {Siqi Chen and Ping Xie and Matthew Cowan and Hao Huang and Horacio Cárdenas and Russell Keathley and Edward J. Tanner and Gini F. Fleming and John W. Moroney and Alok Pant and Azza M. Akasha and Ramana V. Davuluri and Masha Kocherginsky and Bin Zhang and Daniela Matei},
  title = {{Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer}},
  journal = {Journal of Clinical Investigation},
  year = {2022},
  doi = {10.1172/jci158800},
}
Figure